Federal funds can’t be used to give test strips to drug users, raising overdose fears
The Trump administration has told recipients of federal substance-use grants that the money cannot be used to buy drug-testing strips for people using illicit drugs. The strips can detect substances such as fentanyl and other dangerous additives, so public-health groups fear the policy change could remove a low-cost tool that helps prevent overdoses.
The restriction reverses federal support for test strips introduced in 2021 and is part of a wider shift away from harm-reduction services. Test strips cost about $1 each; in Kentucky, one organisation distributed 48,465 in the first quarter of the 2026 financial year before losing a $400,000 grant. US overdose deaths have fallen sharply, from 111,000 in 2023 to roughly 68,000 in the 12 months to November 2025, though experts attribute this to several factors including naloxone, treatment and harm-reduction measures.
- Federal grants can no longer fund drug-testing strips.
- Advocates fear fewer strips could increase overdose risks.
- The change comes despite recent falls in overdose deaths.
Both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Supporters of allowing federal grants to fund drug-testing strips argue that the policy recognises an immediate public-health reality: some people will continue to use illicit drugs, and knowing whether a substance contains fentanyl or another contaminant can help them make safer decisions, avoid using alone or carry naloxone. They contend that inexpensive strips complement treatment and recovery services rather than replace them, and that removing support could disproportionately harm communities already facing high overdose risks.
The case against
Supporters of the restriction may argue that federal substance-use funding should prioritise abstinence, treatment, recovery and law-enforcement approaches rather than supplies associated with ongoing illicit drug use. They may worry that publicly funded testing strips can be interpreted as normalising or facilitating drug consumption, and maintain that scarce resources should focus on helping people stop using drugs altogether. From this perspective, a shift away from harm reduction reflects a belief that durable reductions in overdose deaths require preventing dependence and expanding treatment, not merely reducing the risks of continued use.